Proactive Investors - Run By Investors For Investors

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
board room table surrounded by empty chairs
The board purchases show their confidence in the company's future

Cellmid Ltd (ASX:CDY) has had four of its board members purchase company stock recently with one member buying $1 million worth of shares.

The share purchases were made in a variety of ways including on-market trades and participation in the recent share placement and share purchase plan (SPP).

The board members that increased their holdings were managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck.

Eck acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
genedrive device
Tue
Here we take a closer look at Genedrive PLC (LON:GDR)
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use